

GLAXOSMITHKLINE PLC  
Form 6-K  
April 19, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 19 April 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--



e) Date of the transaction 2017-04-13  
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R G Connor  
 b) Position/status President, Global Manufacturing & Supply  
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882  
 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017, on Ordinary Shares held in the Company's Deferred Investment Award Programme.

b) Nature of the transaction

c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £16.39 230.011  
 n/a (single transaction)

d) Aggregated information  
 Aggregated volume Price

e) Date of the transaction 2017-04-13  
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S A Hussain  
 b) Position/status President, Global Pharmaceuticals  
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
    - ISIN: GB0009252882
    - Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
  - b) Nature of the transaction
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£16.39	287.514
n/a (single transaction)	
  - d) Aggregated information
    - Aggregated volume Price
  - e) Date of the transaction 2017-04-13
  - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr B McNamara
  - b) Position/status CEO, GSK Consumer Healthcare
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053  
 Increase in notional interest  
 in ADSs following the  
 re-investment of dividends  
 paid to shareholders on 13  
 April 2017 on ADSs held in  
 the Company's Deferred  
 Investment Award  
 Programme.

b) Nature of the transaction

c) Price(s) and volume(s)

Price(s)	Volume(s)
\$41.8150	359.648
n/a (single transaction)	

Aggregated information

d)

Aggregated volume Price

e) Date of the transaction

2017-04-13

f) Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

Mr D S Redfern

b) Position/status

Chief Strategy Officer

c) Initial notification/  
 amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction  
 platform, auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of  
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

a) Description of the financial instrument

Ordinary shares of 25 pence  
 each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction

Increase in notional interest  
 in Ordinary Shares following  
 the re-investment of  
 dividends paid to  
 shareholders on 13 April  
 2017 on Ordinary Shares held  
 in the Company's Deferred  
 Investment Award  
 Programme.

c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.39	230.011

n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2017-04-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

b) Position/status Senior Vice President, HR

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.

c) Price(s) and volume(s)  
Price(s) Volume(s)  
£16.39 230.011  
n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2017-04-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr P J T Vallance

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) Position/status President, R&D
- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- ISIN: GB0009252882
- Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
- b) Nature of the transaction
- c) Price(s) and volume(s)
- | Price(s)                 | Volume(s) |
|--------------------------|-----------|
| £16.39                   | 287.514   |
| n/a (single transaction) |           |
- d) Aggregated information
- Aggregated volume Price
- e) Date of the transaction 2017-04-13
- f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 19, 2017

By: VICTORIA WHYTE

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc